{
    "2019-07-05": [
        [
            {
                "time": "2018-01-02",
                "original_text": "复星医药：第八届董事会第二次会议(临时会议)决议公告",
                "features": {
                    "keywords": [
                        "复星医药",
                        "董事会",
                        "决议公告"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-03-15",
                "original_text": "复星医药旗下复宏汉霖赴港IPO，三年亏10亿元，尚无产品销售收入亏损",
                "features": {
                    "keywords": [
                        "复星医药",
                        "复宏汉霖",
                        "IPO",
                        "亏损"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-07-05",
                "original_text": "格隆汇港股聚焦(7.05)︱百威亚太全球拟发行16.26亿股用于还债 融创上半年销售额超2100亿元",
                "features": {
                    "keywords": [
                        "百威亚太",
                        "融创",
                        "发行股份",
                        "还债",
                        "销售额"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "消费品",
                        "房地产"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-10",
                "original_text": "复星医药(600196.SH)：复宏汉霖向联交所呈交经更新的上市申请(A1表格)",
                "features": {
                    "keywords": [
                        "复星医药",
                        "复宏汉霖",
                        "上市申请"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-20",
                "original_text": "复星医药(02196)附属以5.796亿元竞得成都力思特75.9%股权",
                "features": {
                    "keywords": [
                        "复星医药",
                        "成都力思特",
                        "股权收购"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-06-10",
                "original_text": "复星医药(600196.SH)与重药控股订立销售采购协议",
                "features": {
                    "keywords": [
                        "复星医药",
                        "重药控股",
                        "销售采购协议"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-15",
                "original_text": "复星医药(02196.HK)：奥鸿药业拟以5.79亿元收购成都力思特股份75.9085%股权",
                "features": {
                    "keywords": [
                        "复星医药",
                        "奥鸿药业",
                        "成都力思特",
                        "股权收购"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-10",
                "original_text": "复星国际(00656-HK)：复宏汉霖已向联交所呈交经更新上市申请",
                "features": {
                    "keywords": [
                        "复星国际",
                        "复宏汉霖",
                        "上市申请"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-07-01",
                "original_text": "【华泰医药代雯团队】《第一批国家重点监控合理用药药品目录》点评：靴子落地",
                "features": {
                    "keywords": [
                        "华泰医药",
                        "合理用药",
                        "药品目录",
                        "政策"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-07-05",
                "original_text": "华泰证券：靴子落地 第一批监控用药目录出台",
                "features": {
                    "keywords": [
                        "华泰证券",
                        "监控用药",
                        "目录出台",
                        "政策"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-09-10",
                "original_text": "复星医药总裁兼CEO吴以芳：加速创新，提升产品力和品牌力",
                "features": {
                    "keywords": [
                        "复星医药",
                        "吴以芳",
                        "创新",
                        "产品力",
                        "品牌力"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}